Рынок хондросаркомы вырастет к 2036 году благодаря таргетной терапии мутаций IDH

Chondrosarcoma Market is Projected to Witness Significant Growth by 2036 Owing to the Emergence of Targeted Therapies and Growing Focus on IDH-mutant Disease | DelveInsight 09-05-2026 02:22 PM CET | Associations & Organizations Press release from: ABNewswire The market dynamics for Chondrosarcoma are witnessing steady growth driven by increasing detection rates, advances in imaging and diagnostic sensitivity, growing understanding of the molecular drivers of the disease, and the significant unmet need for effective systemic therapies. (Albany, New York)- 5th Sep 2026, The market dynamics for Chondrosarcoma are witnessing steady growth driven by increasing detection rates, advances in imaging and diagnostic sensitivity, growing understanding of the molecular drivers of the disease, and the significant unmet need for effective systemic therapies. Additionally, the development of promising targeted therapies such as Ivosidenib and INBRX-109 (Ozekibart), along with increasing focus on IDH1/2 mutations, EZH2 inhibition, and DR5-targeted approaches, is expected to further propel the Chondrosarcoma market during the forecast period. DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Chondrosarcoma Market Insights, Epidemiology and Market Forecast - 2036." This comprehensive report provides an in-depth understanding of Chondrosarcoma, including historical and forecasted epidemiology, market trends, treatment scenarios, patient burden, and competitive landscape across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. Key Takeaways from the Chondrosarcoma Market * The market size for Chondrosarcoma in the leading markets is expected to grow significantly by 2036. * The 7MM Chondrosarcoma market was approximately USD 15 million in 2025 and is projected to grow at a 16% CAGR during 2026-2036. * According to DelveInsight's estimates, the total incident cases of Chondrosarcoma in the 7MM were approximately 2,300 in 2025. * Chondrosarcoma primarily affects adults and is the second most common primary solid tumor of bone after osteogenic sarcoma. * In 2025, conventional Chondrosarcoma accounted for approximately 80% of all Chondrosarcoma cases, making it the most prevalent subtype. * Chondrosarcoma is categorized into Grades I, II, III, and IV, with the majority of cases falling within Grade II. * IDH mutations are found in approximately 50-70% of Chondrosarcoma cases, making IDH-targeted therapies an important area of therapeutic development. * In 2025, the United States accounted for the largest Chondrosarcoma market size among the 7MM, with approximately USD 10 million in market revenue. * There are currently no approved drugs specifically for the treatment of Chondrosarcoma, creating significant unmet medical needs and opportunities for emerging targeted therapies. * Surgery remains the mainstay of treatment, while radiotherapy and chemotherapy have limited effectiveness, particularly in conventional Chondrosarcoma. * Ivosidenib, developed by Servier, is being evaluated in a Phase III study for patients with IDH1-mutant conventional Chondrosarcoma, targeting a genetically defined patient population with significant unmet need. * INBRX-109 (Ozekibart), developed by Inhibrx, is a DR5 agonist antibody currently being evaluated in a potentially registration-enabling Phase II trial for Chondrosarcoma. * Leading Chondrosarcoma companies, including Servier, Inhibrx, and others, are actively developing innovative therapies expected to transform the Chondrosarcoma treatment landscape over the coming years. * Promising Chondrosarcoma therapies in clinical development include Ivosidenib and INBRX-109 (Ozekibart). Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/chondrosarcoma-market [ https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr ] Key Factors Driving the Chondrosarcoma Market Rising Disease Detection and Diagnosis Increased detection rates supported by advanced imaging and improved diagnostic sensitivity are contributing to higher reported cases of Chondrosarcoma. The use of X-rays, CT scans, MRI scans, and biopsy enables clinicians to visualize tumors, assess their extent, confirm diagnosis, and determine tumor grade. Emergence of Targeted Therapies Research into molecularly targeted therapies is creating new opportunities in Chondrosarcoma treatment. IDH1/2 inhibitors such as Ivosidenib, EZH2 inhibitors, and DR5-targeted agents such as INBRX-109 are being developed to address specific biological mechanisms involved in tumor development. Growing Focus on IDH-mutant Chondrosarcoma The high frequency of IDH mutations in Chondrosarcoma has created a strong rationale for developing mutation-specific treatments. The advancement of Ivosidenib into Phase III clinical development represents an important step toward targeted treatment for patients with IDH1-mutant disease. Significant Unmet Need for Effective Systemic Therapy Surgery remains the primary curative approach, while conventional Chondrosarcoma is generally resistant to chemotherapy and radiotherapy. The absence of effective systemic therapy for advanced disease and limited treatment options for aggressive and metastatic cases create substantial opportunities for novel therapies. Chondrosarcoma Competitive Landscape The Chondrosarcoma treatment landscape is primarily centered on surgical management, with the type, grade, and location of the tumor determining treatment and prognosis. Wide compartmental tumor resection remains the principal curative treatment, while curettage, radical resection, and amputation may be considered depending on tumor characteristics. Radiotherapy and chemotherapy have limited effectiveness in conventional Chondrosarcoma because of the disease's resistance to these approaches. Chemotherapy may have a role in selected aggressive subtypes, particularly dedifferentiated Chondrosarcoma, where regimens based on doxorubicin, cisplatin, or ifosfamide may be considered. The emerging landscape is increasingly focused on targeted approaches. Ivosidenib, developed by Servier, is an oral IDH1 inhibitor being evaluated in a Phase III clinical trial for patients with locally advanced or metastatic conventional Chondrosarcoma harboring an IDH1 mutation. INBRX-109 (Ozekibart), developed by Inhibrx, is a tetravalent DR5 agonist antibody designed to induce tumor cell death through efficient DR5 receptor clustering. The therapy is currently being evaluated in a potentially registration-enabling Phase II trial in Chondrosarcoma. These emerging targeted therapies are expected to further reshape the Chondrosarcoma treatment landscape over the forecast period. Discover more about therapies set to grab major Chondrosarcoma market share @ Chondrosarcoma Treatment Landscape [ https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr ] Recent Developments in the Chondrosarcoma Market * In October 2025, Inhibrx announced positive data from the INBRX-109 (Ozekibart) registration-enabling trial in patients with advanced or metastatic, unresectable Chondrosarcoma. Key data and milestone events were expected in 2026. * In January 2025, Servier announced an update to its Phase III program evaluating TIBSOVO (Ivosidenib) in IDH1-mutated cancers. The first patient had been enrolled in the CHONQUER study, a pivotal Phase III clinical trial evaluating Ivosidenib versus placebo in patients with IDH1-mutated conventional Chondrosarcoma. What is Chondrosarcoma? Chondrosarcoma is a group of locally aggressive or malignant tumors that produce a cartilaginous matrix. It is the most common sarcoma of bone in patients above the age of 20 and predominantly affects individuals in the fourth to sixth decades of life. Chondrosarcoma most commonly develops in the pelvic bones, followed by the femur, humerus, and ribs. The disease may be classified as primary or secondary, depending on whether the tumor develops de novo or arises from a preexisting benign cartilage neoplasm. The disease can be categorized into different grades based on tumor characteristics and aggressiveness. Grade II represents the majority of cases, while aggressive subtypes may demonstrate local recurrence and metastatic progression. Diagnosis involves a combination of medical history, physical examination, X-rays, CT scans, MRI scans, and biopsy. Tissue obtained through biopsy is examined by a pathologist to confirm the diagnosis and determine tumor grade. Staging assessments may subsequently be conducted to evaluate disease spread. Treatment depends on tumor type, grade, and location. Surgery is the primary treatment, while chemotherapy and radiotherapy have limited roles because conventional Chondrosarcoma is generally resistant to these approaches. The development of targeted therapies addressing molecular abnormalities represents an important area of ongoing research. Chondrosarcoma Epidemiology Segmentation The Chondrosarcoma epidemiology section provides insights into the historical and current Chondrosarcoma patient pool and forecasted trends across the seven major markets. The Chondrosarcoma market report provides epidemiological analysis for the study period 2022-2036, segmented into: * Total Incident Cases of Chondrosarcoma * Primary Incident Cases of Chondrosarcoma * Grade-specific Incident Cases of Chondrosarcoma * Mutation-specific Incident Cases of Chondrosarcoma * Stage-specific Incident Cases of Chondrosarcoma * Patient Burden Assessment Scope of the Chondrosarcoma Market Report * Therapeutic Assessment: Current treatment approaches and emerging therapies for Chondrosarcoma * Chondrosarcoma Market Dynamics: Key market forecast assumptions, pricing trends, analogue assessment, therapy uptake, and market outlook * Key Companies: Servier, Inhibrx, and others * Key Therapies: Ivosidenib, INBRX-109 (Ozekibart), and others * Competitive Intelligence Analysis: SWOT Analysis and Conjoint Analysis * Unmet Needs, KOL's Views, Analyst's Views, Chondrosarcoma Market Access and Reimbursement To know more about Chondrosarcoma companies working in the treatment market, visit @ Chondrosarcoma Clinical Trials and Therapeutic Assessment [ https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr ] Table of Contents * Chondrosarcoma Market Report Introduction * Executive Summary for Chondrosarcoma * Key Events of Chondrosarcoma * Epidemiology and Market Methodology of Chondrosarcoma * Chondrosarcoma Market Overview at a Glance * Clinical Landscape Analysis * Chondrosarcoma Background and Overview * Types of Chondrosarcoma * Molecular Classification of Chondrosarcoma * Causes * Signs and Symptoms * Diagnosis * Differential Diagnosis * Diagnostic Algorithm * Diagnostic Guidelines * Chondrosarcoma Epidemiology and Patient Population * Country-Specific Patient Population of Chondrosarcoma * Chondrosarcoma Current Treatment and Medical Practices * Chondrosarcoma Unmet Needs * Chondrosarcoma Emerging Therapies * Chondrosarcoma Market Outlook * Country-Wise Chondrosarcoma Market Analysis (2022-2036) * Chondrosarcoma Market Access and Reimbursement of Therapies * Chondrosarcoma Market Drivers * Chondrosarcoma Market Barriers * Chondrosarcoma Appendix * Chondrosarcoma Report Methodology * DelveInsight Capabilities * Disclaimer * About DelveInsight About DelveInsight DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Kirti Sharma Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=chondrosarcoma-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-emergence-of-targeted-therapies-and-growing-focus-on-idhmutant-disease-delveinsight ] Phone: 9193216187 Address:304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website: https://www.delveinsight.com/ Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact [email protected] This release was published on openPR. Permanent link to this press release: Copy Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release. You can edit or delete your press release Chondrosarcoma Market is Projected to Witness Significant Growth by 2036 Owing to the Emergence of Targeted Therapies and Growing Focus on IDH-mutant Disease | DelveInsight here News-ID: 4622938 • Views: … 09-05-2026 | Health & Medicine ABNewswire The Global Intracardiac Echocardiography Devices Market Size is projected to gro … The Intracardiac Echocardiography Devices market is estimated to grow at a CAGR of 5.33% during the forecast period from 2024 to 2030. Growth is anchored in the increasing prevalence of arrhythmia, atrial septal defects, and other cardiovascular diseases, alongside rising demand for minimally invasive approaches. (Albany, New York)- 5th Sep 2026, DelveInsight's Intracardiac Echocardiography Devices Market Insights Report 2030 provides the current and forecast market analysis, individual leading Intracardiac Echocardiography Devices … 09-05-2026 | Associations & Organizations ABNewswire Glioblastoma Multiforme Market is Projected to Reach USD 4,800 Million by 2036, … DelveInsight's latest report, "Glioblastoma Multiforme Market Insight, Epidemiology and Market Forecast - 2036," provides a comprehensive analysis of the Glioblastoma Multiforme (GBM) market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight's estimates, the Glioblastoma Multiforme market size in the 7MM was approximately USD 900 million in 2025 and is projected to reach approximately USD 4,800 million by 2036. (Albany, New York)- … 09-05-2026 | Health & Medicine ABNewswire Progressive Supranuclear Palsy Market Expected to Gain Momentum Through 2036, Ac … The Progressive Supranuclear Palsy Market Report provides real-world prescription pattern analysis, emerging therapies, market share of individual treatments, and historical and forecasted 7MM Progressive Supranuclear Palsy market size from 2022 to 2036. The report also covers current treatment practices, clinical trials, unmet medical needs, market drivers, barriers, and competitive intelligence to help stakeholders identify future growth opportunities. (Albany, New York)- 5th Sep 2026, DelveInsight's Progressive Supranuclear Palsy Market Insights, Epidemiology, and … 09-05-2026 | Associations & Organizations ABNewswire Hemophilia B Market is Projected to Witness Significant Growth by 2036 Owing to … The market dynamics for Hemophilia B are witnessing steady growth driven by advancements in diagnostic capabilities, increasing disease awareness, improved access to specialized care centers, and the growing adoption of prophylactic treatment. (Albany, New York)- 5th Sep 2026, The market dynamics for Hemophilia B are witnessing steady growth driven by advancements in diagnostic capabilities, increasing disease awareness, improved access to specialized care centers, and the growing adoption of prophylactic treatment. Additionally, … All 5 Releases 07-16-2026 | Health & Medicine DelveInsight Business Research LLP Chondrosarcoma Pipeline, Treatment Market, and Emerging Drug Landscape Analysis: … DelveInsight's Chondrosarcoma Pipeline Insight 2026 report provides comprehensive global coverage of marketed and pipeline therapies for Chondrosarcoma across various stages of clinical development. The report delivers in-depth insights into the evolving Chondrosarcoma treatment landscape, emerging therapies, pipeline innovations, market trends, competitive intelligence, and future growth opportunities shaping the Chondrosarcoma market and bone cancer therapeutics industry. Key Takeaways from the Chondrosarcoma Pipeline and Treatment Landscape Report • DelveInsight's Chondrosarcoma pipeline analysis highlights a growing … 05-12-2025 | Health & Medicine DelveInsight Chondrosarcoma Pipeline: Advancing Therapeutics and 15+ Leading Companies Shapin … The therapeutic landscape for Chondrosarcoma, a rare and aggressive bone cancer, is rapidly evolving, driven by advances in molecular biology, targeted therapies, and a deeper understanding of the tumor's genetic and cellular mechanisms. Leading biopharmaceutical companies like PharmaMar and Salarius Pharmaceuticals are at the forefront, focusing on innovative approaches to target key pathways such as cartilage-specific mutations, tumor microenvironment modulation, and immune checkpoint inhibition for the treatment of Chondrosarcoma. DelveInsight's "Chondrosarcoma … 03-28-2023 | Health & Medicine DelveInsight Business Research Chondrosarcoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse C … DelveInsight's, "Chondrosarcoma Pipeline Insight, 2023," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Chondrosarcoma pipeline landscape. It covers the Chondrosarcoma pipeline drug profiles, including Chondrosarcoma clinical trials and nonclinical stage products. It also covers the Chondrosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. For Chondrosarcoma emerging drugs, the Chondrosarcoma … 07-10-2017 | Health & Medicine Persistence Market Research Chondrosarcoma Treatment Market Rugged Expansion Foreseen by 2022 Chondrosarcoma refers to cancer of cartilage, a flexible connective tissue found in joints between bones, the ear, the rib cage etc. According to Cancer Network Journal, chondrosarcoma contributes to almost half of the osteosarcoma cases and is the second most common type of osteosacrcoma (tumor of bones). Chondrosarcoma can start at any age but most commonly found in adults above the age of 20 years. As per the statistics of … 06-12-2017 | Health & Medicine Pharmaceutical Market Reports - MRH Chondrosarcoma - Pipeline Review, H1 2017 - Pharmaceutical Market Report Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, changes in urination. Treatment includes chemotherapy and radiation therapy. Request Free Sample … 05-25-2017 | Health & Medicine Persistence Market Research Chondrosarcoma Treatment Market is Growing at Significant Rate by 2022 Chondrosarcoma refers to cancer of cartilage, a flexible connective tissue found in joints between bones, the ear, the rib cage etc. According to Cancer Network Journal, chondrosarcoma contributes to almost half of the osteosarcoma cases and is the second most common type of osteosacrcoma (tumor of bones). Chondrosarcoma can start at any age but most commonly found in adults above the age of 20 years. As per the statistics of …